CN116715760A - Monoclonal antibody of anti-influenza B virus nucleocapsid protein and application thereof - Google Patents

Monoclonal antibody of anti-influenza B virus nucleocapsid protein and application thereof Download PDF

Info

Publication number
CN116715760A
CN116715760A CN202310946040.4A CN202310946040A CN116715760A CN 116715760 A CN116715760 A CN 116715760A CN 202310946040 A CN202310946040 A CN 202310946040A CN 116715760 A CN116715760 A CN 116715760A
Authority
CN
China
Prior art keywords
influenza
clone
antibody
virus
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202310946040.4A
Other languages
Chinese (zh)
Other versions
CN116715760B (en
Inventor
芮兵
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Baikang Biotechnology Co ltd
Original Assignee
Nanjing Baikang Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Baikang Biotechnology Co ltd filed Critical Nanjing Baikang Biotechnology Co ltd
Priority to CN202310946040.4A priority Critical patent/CN116715760B/en
Publication of CN116715760A publication Critical patent/CN116715760A/en
Application granted granted Critical
Publication of CN116715760B publication Critical patent/CN116715760B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G01N33/54386—Analytical elements
    • G01N33/54387—Immunochromatographic test strips
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/11—Orthomyxoviridae, e.g. influenza virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The invention discloses a monoclonal antibody of anti-influenza B virus nucleocapsid protein and application thereof, comprising a No.1 clone antibody and a No.2 clone antibody, wherein the amino acid sequence of a heavy chain variable region of the No.1 clone is shown as SEQ ID NO.1, and the amino acid sequence of a light chain variable region of the No.1 clone is shown as SEQ ID NO. 2; the amino acid sequence of the heavy chain variable region of clone No.2 is shown as SEQ ID NO.3, and the amino acid sequence of the light chain variable region of clone No.2 is shown as SEQ ID NO. 4. The monoclonal antibody of the anti-influenza B virus nucleocapsid protein has the characteristics of specificity and high affinity, and simultaneously provides a diagnostic detection kit based on the antibody, thereby improving the specificity and sensitivity of a diagnostic reagent.

Description

Monoclonal antibody of anti-influenza B virus nucleocapsid protein and application thereof
Technical Field
The invention belongs to the field of antibody preparation and sequence determination, and in particular relates to a monoclonal antibody of anti-influenza B virus nucleocapsid protein and application thereof.
Background
Influenza viruses (Influenza viruses) belong to the genus Influenza virus of the family orthomyxoviridae, and can be classified into Influenza a virus (Influenza A virus), influenza b virus (Influenza B virus), influenza c virus (Influenza C virus) and Influenza d virus (Influenza D virus) according to their different properties of Nucleocapsid Protein (NP) and Matrix protein (M). After the influenza virus enters a host body through the respiratory tract, the influenza virus invades cells through the combination of the HA protein on the surface and the specific receptor on the cell surface, then the viral genome begins to translate by means of the raw materials in the cells to code various proteins for vital activities of the influenza virus, symptoms such as cough, nasal discharge, sore throat and the like can occur after infection, various diseases such as bronchus related inflammation and even pneumonia can also be caused, so that life is endangered, the influenza virus HAs higher pathogenic mortality, the influenza B accounts for about 25% of the total incidence of the influenza, the severity of the caused diseases is equivalent to the influenza A, and the influenza B is divided into two lineages: the Yamagata line and Victoria line tend to alternate between the two lineages.
The influenza virus Nucleoprotein (NP) is composed of 5 th gene code, 498 amino acids, is an important structural protein of influenza virus, accounts for about 25% of virus particles, is highly conserved in two Yamagata and Victoria lineages, has high amino acid homology, can be used for differential diagnosis of influenza virus types, and is the most representative protein for diagnosing influenza viruses. Has high immunogenicity and can be used for preparing monoclonal antibodies for diagnosis.
The core raw material of the influenza B diagnostic reagent is a monoclonal antibody of NP protein, the specificity and the sensitivity of general manufacturers are not high, the content of the influenza B virus cannot be accurately detected, and the condition of omission is caused, so that the development and development of the influenza B diagnostic reagent with excellent performance are very necessary.
Disclosure of Invention
In order to solve the problems of sensitivity and specificity, the invention provides a monoclonal antibody of anti-influenza B virus nucleocapsid protein. The antibody has excellent performance and high accuracy.
Meanwhile, the influenza B virus antigen detection kit is provided, so that the content of the influenza B virus can be accurately detected, and a basis is provided for influenza B diagnosis.
The invention provides the following technical scheme:
monoclonal antibodies against influenza B nucleocapsid proteins, including clone No.1 and clone No.2,
heavy chain variable region amino acid sequence of clone No. 1:
EVQLQQSGPDLVKPGASVEMSCKASGYTFTIYVIHWVKQKPGQGLEWIGYINPYNDGAKYNEMFKGKATLTSDKSSSTAYMELSSLTSEDSAVYYCAREDWLRFDYWGQGTTLTVSS
light chain variable region amino acid sequence of clone No. 1:
DIVLTQSPATLSVTPGDSVSLSCRASQSISNNLHWYQQKSHESPRLLIKFASQSISGIPSRFSGSGSGADFTLSINSVETEDFGMYFCQQSNSWPRTFGGGTKLEVK
heavy chain variable region amino acid sequence of clone No. 2:
EIQLQQSGPELVKPGASVTVSCKASGYSFTDYNMYWVKQSHGKSLEWIGYFDPYNGGSNYNQKFKGKATLTVDKSSSTAFMHLNSLTSEDSAVYYCARDAYYFGSIYVMDYWGQGTSVTVSS
light chain variable region amino acid sequence of clone No. 2:
DIVMTQSHKIMSTSVGDRVSITCKASQDVSTAVGWYQQKPGHSPKLLIYSASSRYTGVPDRFTGSGSGTEFTFTISSVQAEDLAAYFCQQHYSSPFTFGSETKLEIK
the application of monoclonal antibody against influenza B virus nucleocapsid protein in preparing influenza B diagnostic reagent. The monoclonal antibody is used for influenza B virus antigen detection kit.
The influenza B virus antigen detection kit uses clone No.1 and clone No.2 as detection antibodies and coatings respectively.
The marked clone No.1 antibody is uniformly fixed on a bonding pad by using a metal spraying instrument; preparing a coating liquid of the No.2 clone antibody by using trehalose, and uniformly fixing the coating liquid on an NC film by using a continuous film-scratching instrument; the water absorbing paper, NC film, combining pad and sample pad are assembled into a large plate, the large plate is chopped into reagent strips by a slitter, and the reagent strips are put into a card shell to form the reagent kit.
The marking method comprises the following steps: treating red latex microspheres with an activation buffer solution, transferring the latex microspheres to a clean centrifuge tube after activation, centrifuging at normal temperature, discarding the supernatant, adding a phosphate buffer solution of a marking buffer solution, neutralizing pH, adding water bath ultrasound by vortex to uniformly mix the latex, transferring the latex to a clean container, adding a No.1 clone antibody under stirring, and continuously reacting.
Compared with the prior art, the invention has the beneficial effects that: the invention provides anti-influenza B virus nucleocapsid protein, which has population and type specificity and very high immunogenicity, is used for preparing a monoclonal antibody for diagnosis and is used for differential diagnosis of influenza virus types. Has great clinical significance for diagnosis and epidemiological investigation of influenza B virus.
Description of the embodiments
The technical solutions of the embodiments of the present invention will be clearly and completely described below in conjunction with the embodiments of the present invention, and it is apparent that the described embodiments are only some embodiments of the present invention, not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
Example 1 construction of NP protein expression vectors
Searching the NP protein amino acid sequence of the influenza B virus on NCBI functional network, adding histidine tag on the protein amino acid, optimizing codon in an escherichia coli expression system by utilizing codon optimizing software, cloning the gene into a pET30a expression vector by utilizing NdeI & XhoI restriction enzyme cleavage site after gene synthesis, constructing pET30a-FluB NP expression plasmid, and sequencing and verifying the gene sequence.
Example 2 expression production of NP protein
Transforming competent cells of Escherichia coli BL21 (DE 3) with pET30a-FluB NP expression plasmid, picking single colony for induction expression, culturing in LB culture medium containing 50ug/ml kanamycin, culturing at 37deg.C and 220 rpm until OD600nm to 0.6-0.8, adding 0.2mM isopropyl thiogalactoside（IPTG）Performing induction expression, inducing at 37 ℃ for 6 hours, centrifuging for 10min and collecting thalli at 8000 g.
Example 3 affinity purification of NP protein
The cells were resuspended in 20mM PB,300mM NaCl,10% glycerol, pH8.0 buffer, homogenized under high pressure at 800bar, 12000g, centrifuged for 30min, the supernatant was collected, affinity purified using a gravity column Ni Smart-6FF beads, 20mM PB,300mM NaCl,10% glycerol, 50mM imidazole, pH8.0 solution, 20mM PB,300mM NaCl,10% glycerol, 250mM imidazole, pH8.0 solution, eluted, subjected to SDS-PAGE electrophoresis, protein purity was detected, and the protein was dialyzed to 20mM PB,300mM NaCl,10% glycerol, pH8.0 buffer, sterile filtered using a 0.22um filter, and then the protein concentration was determined by BCA.
EXAMPLE 4 preparation of monoclonal antibodies
Mixing and emulsifying proteins and Freund's adjuvant in equal volume, performing subcutaneous multipoint injection for 3 weeks, performing boosting immunization, performing subcutaneous multipoint injection for 50 ug/mouse, collecting blood serum of the mouse every 2 weeks later, ELISA detection antibody titer, screening immunized mice for hybridoma fusion experiment, screening and culturing by about 10 days of HAT screening culture medium, taking supernatant for ELISA detection, screening out positive cell strains with better performance, performing two rounds of cell subcloning, cloning monoclonal cell strains, culturing and fermenting cell strains without serum, collecting culture supernatant, performing antibody purification, and performing diagnostic performance analysis on the purified antibodies.
EXAMPLE 5 monoclonal antibody Performance analysis
The preparation method of the bonding pad comprises the following steps:
this protocol takes the preparation of 100ml of finished latex particles as an example, with a labeling temperature of 37 ℃.
(1) Activating: placing the clean beaker on a magnetic stirrer, placing a magnetic stirrer in a container, adding 40ml of an activation buffer (0.05M MES pH 6.0), sequentially adding 5ml of red latex microspheres, 2ml of 10mg/ml NHS and 2ml of 10mg/ml EDC while stirring, and stirring for reaction for 30min;
(2) Marking: after the activation, transferring the latex into a clean centrifuge tube, centrifuging at normal temperature of 12000rpm for 30min, removing the supernatant, adding 40ml of marking buffer solution 20mM PB (pH 7.5), and adding water bath ultrasound by vortex to uniformly mix the latex. Transferring the emulsion into a clean container, adding 20mg of clone No.1 antibody under stirring, and continuously reacting for 1 hour;
(3) Closing: 2ml of 10% BSA was added to the above reaction system and the reaction was continued with stirring for 0.5 hour;
(4) Cleaning: after the reaction, the latex was transferred to a centrifuge tube, centrifuged at 12000rpm for 30min at room temperature, and 40ml of 20mmTris (pH 8.5) was added after the supernatant was completely discarded, and the latex was mixed uniformly by vortexing and ultrasonic in a water bath. The latex is centrifuged again at the normal temperature of 12000rpm for 20min, 40ml of 20mmTris+3% trehalose is added after the supernatant is completely discarded, and the latex is evenly mixed by vortex and water bath ultrasonic. An ultrasonic cell grinder is used for preparing a No.2 ultrasonic probe, 30% power, 5 second ultrasonic and 3 second interval parameters are set, and the marker is treated by ultrasonic for 10min. The marking work is completed by adjusting the volume of the latex after ultrasonic treatment to 100 ml;
(5) Preparing a bonding pad: the labeled clone No.1 antibody is uniformly fixed on a bonding pad by using a metal spraying instrument according to the concentration of 2ul/cm, and is dried at 37 ℃ for 20min, dried, sealed and stored.
The coating method comprises the following steps:
(1) Sticking film: cutting a rolled NC film into sections with the length of about 31cm by using scissors, tearing off a protective film with the width of 2.5cm in the middle of a PVC adhesive plate on a horizontal tabletop, slightly holding two ends of a nitrocellulose film (NC film) by two hands, aligning knife edge lines, neatly attaching the NC film to the PVC adhesive plate, placing two adhesive plates attached with the NC film face to face, and collecting in a bundle;
(2) And (3) film drawing: the clone No.2 antibody is prepared into a membrane drawing liquid with the final concentration of the antibody of 1mg/ml by using a coating liquid (20 mmPB 1% trehalose), and the coating liquid is uniformly fixed on an NC membrane by using a continuous membrane drawing instrument;
(3) Drying and packaging: after scribing, placing NC film into room with room temperature of 18-26 ℃ and relative humidity of 20-28%, drying for 30min, and binding 20-50 sheets of adhesive tape; placing the glue plate after each bale is packed into an aluminum foil bag, sealing after a drying agent is placed, marking names, production dates, quantity and the like on the aluminum foil bag after the encapsulation is finished, and storing into an intermediate warehouse for recording;
(4) And (3) assembling: the water absorbing paper, NC film, combining pad and sample pad are assembled into a large plate, the large plate is chopped into reagent strips by a slitter and is put into a clamping shell, and the relative humidity of the assembly environment is 20% -28%.
Preparing a reference:
diluting influenza B N protein to 0, 400, 1600 and pg/ml respectively by using an extracting solution to prepare a reference with the lowest detection limit;
the extracting solution is used for respectively releasing the N protein thin liquid of the influenza B to 1600, 15000 and pg/ml to prepare a repetitive reference;
respectively releasing influenza B N protein dilute to 400, 800, 1600, 6400, 25000 and 102400pg/ml by using the extracting solution to prepare positive reference substances;
10 normal human nasopharyngeal swabs which are not infected with influenza B are prepared into negative reference products by using the extracting solution;
the above extract formulation was 100mM PB, 150mM NaCl, 5% BSA, 10% Glycerin, 0.5% procin300, pH=8.0.
Comparing the detection reagent with the similar products:
the current domestic and foreign influenza B virus detection kit mainly comprises a colloidal gold method and a PCR method, and the influenza B virus antigen detection kit (latex method) in the embodiment performs correlation comparison on 231 clinical specimens, as shown in the table 1, and the antibody clinical performance test results are as follows:
TABLE 1 results of antibody clinical Performance test
Analysis results:
sensitivity= 91.34% (95% CI: 85.15% -95.09%)
Specificity = 96.46% (95% CI: 91.25% -98.62%)
Accuracy=93.75% (95% CI: 89.95% -96.18%)
The reagent disclosed by the invention can accurately detect the content of the influenza B virus, provides a basis for influenza B diagnosis, and can fully meet the clinical in-vitro diagnosis and detection requirements.
Detection reagent sensitivity and precision investigation
The sensitivity of the kit in the invention is researched according to the national medical supervision center 'qualitative detection in vitro diagnostic reagent analysis performance evaluation registration examination guiding principle', and the result shows that the lowest detection limit is 400pg/mL respectively.
The repeated research of the kit in the invention is carried out according to the principles of qualitative detection in vitro diagnostic reagent analysis performance evaluation registration and examination guidance of the national drug administration organ review center, and the detection results are consistent in color development.
The monoclonal antibody of the NP protein which is a core raw material of the influenza B diagnostic reagent with excellent development performance is required to eliminate cross reaction of other common viruses such as influenza A virus and the like, and ensures the specificity and high affinity of the monoclonal antibody, thereby improving the specificity and sensitivity of the diagnostic reagent and having great clinical significance for diagnosis and epidemiological investigation of the influenza B virus.
Detection reagent interference resistance analysis:
has no cross reaction with common respiratory tract virus and mycoplasma pneumoniae.
The viruses and bacteria tested were as follows:
influenza A virus
Respiratory syncytial virus
Parainfluenza virus
Adenovirus
Staphylococcus aureus
Neisseria meningitidis
Streptococcus pneumoniae
Seasonal H1N1
- -A-type H3N2
--2009H1N1
Has no cross reaction with common respiratory tract virus and mycoplasma pneumoniae. The kit is used for qualitative detection, and the cross reaction experiment kit only shows the C line, namely negative.

Claims (7)

1. A monoclonal antibody against influenza b nucleocapsid protein, characterized in that: including clone No.1 and clone No.2,
the amino acid sequence of the heavy chain variable region of the No.1 clone antibody is shown as SEQ ID NO.1, and the amino acid sequence of the light chain variable region of the No.1 clone antibody is shown as SEQ ID NO. 2;
the amino acid sequence of the heavy chain variable region of the No.2 clone antibody is shown as SEQ ID NO.3, and the amino acid sequence of the light chain variable region of the No.2 clone antibody is shown as SEQ ID NO. 4.
2. Use of the monoclonal antibody against influenza b virus nucleocapsid protein according to claim 1 for the preparation of an influenza b diagnostic reagent.
3. Use of a monoclonal antibody against influenza b virus nucleocapsid protein according to claim 2 for the preparation of an influenza b diagnostic reagent, characterized in that: the monoclonal antibody is used for influenza B virus antigen detection kit.
4. The influenza B virus antigen detection kit is characterized in that: comprising the clone 1 and clone 2 antibodies according to claim 1.
5. The influenza b virus antigen detection kit as claimed in claim 4, wherein: the kit uses a No.1 clone antibody and a No.2 clone antibody as a detection antibody and a coating, respectively.
6. The influenza b virus antigen detection kit as claimed in claim 5, wherein: the marked clone No.1 antibody is uniformly fixed on a bonding pad by using a metal spraying instrument; preparing a coating liquid of the No.2 clone antibody by using trehalose, and uniformly fixing the coating liquid on an NC film by using a continuous film-scratching instrument; the water absorbing paper, NC film, combining pad and sample pad are assembled into a large plate, the large plate is chopped into reagent strips by a slitter, and the reagent strips are put into a card shell to form the reagent kit.
7. The influenza b virus antigen detection kit as claimed in claim 6, wherein: the marking method comprises the following steps: treating red latex microspheres with an activation buffer solution, transferring the latex microspheres to a clean centrifuge tube after activation, centrifuging at normal temperature, discarding the supernatant, adding a phosphate buffer solution of a marking buffer solution, neutralizing pH, adding water bath ultrasound by vortex to uniformly mix the latex, transferring the latex to a clean container, adding a No.1 clone antibody under stirring, and continuously reacting.
CN202310946040.4A 2023-07-31 2023-07-31 Monoclonal antibody composition for resisting influenza B virus nucleocapsid protein and application thereof Active CN116715760B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310946040.4A CN116715760B (en) 2023-07-31 2023-07-31 Monoclonal antibody composition for resisting influenza B virus nucleocapsid protein and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202310946040.4A CN116715760B (en) 2023-07-31 2023-07-31 Monoclonal antibody composition for resisting influenza B virus nucleocapsid protein and application thereof

Publications (2)

Publication Number Publication Date
CN116715760A true CN116715760A (en) 2023-09-08
CN116715760B CN116715760B (en) 2023-10-03

Family

ID=87873691

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202310946040.4A Active CN116715760B (en) 2023-07-31 2023-07-31 Monoclonal antibody composition for resisting influenza B virus nucleocapsid protein and application thereof

Country Status (1)

Country Link
CN (1) CN116715760B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117143242A (en) * 2023-10-30 2023-12-01 南京佰抗生物科技有限公司 Monoclonal antibody composition for resisting Galectin-3 protein and application thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1591015A (en) * 2003-09-03 2005-03-09 北京阿斯可来生物工程有限公司 Influenza Virus B colloidal gold quick detection test paper
CN102197306A (en) * 2008-10-24 2011-09-21 富士胶片株式会社 Immobilization substrate and method for producing the same
US20190345230A1 (en) * 2015-06-03 2019-11-14 Xiamen University Broad-spectrum monoclonal anti-flu b antibody and uses thereof
US20210247395A1 (en) * 2018-06-11 2021-08-12 Glaxosmithkline Consumer Healthcare Holdings (Us) Llc Antibody pairs for use in a rapid influenza b diagnostic test
WO2023040026A1 (en) * 2021-09-15 2023-03-23 杭州宝临生物科技有限公司 Immunochromatographic detection reagent strip and kit comprising same, and applications of both
CN115838421A (en) * 2022-11-15 2023-03-24 杭州华葵金配生物科技有限公司 Antibody targeting influenza B virus nucleoprotein and application thereof
CN115947835A (en) * 2022-11-15 2023-04-11 杭州华葵金配生物科技有限公司 Antibody targeting influenza B virus nucleoprotein and application thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1591015A (en) * 2003-09-03 2005-03-09 北京阿斯可来生物工程有限公司 Influenza Virus B colloidal gold quick detection test paper
CN102197306A (en) * 2008-10-24 2011-09-21 富士胶片株式会社 Immobilization substrate and method for producing the same
US20190345230A1 (en) * 2015-06-03 2019-11-14 Xiamen University Broad-spectrum monoclonal anti-flu b antibody and uses thereof
US20210247395A1 (en) * 2018-06-11 2021-08-12 Glaxosmithkline Consumer Healthcare Holdings (Us) Llc Antibody pairs for use in a rapid influenza b diagnostic test
WO2023040026A1 (en) * 2021-09-15 2023-03-23 杭州宝临生物科技有限公司 Immunochromatographic detection reagent strip and kit comprising same, and applications of both
CN115838421A (en) * 2022-11-15 2023-03-24 杭州华葵金配生物科技有限公司 Antibody targeting influenza B virus nucleoprotein and application thereof
CN115947835A (en) * 2022-11-15 2023-04-11 杭州华葵金配生物科技有限公司 Antibody targeting influenza B virus nucleoprotein and application thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BAI GR等: "Improvement of a rapid diagnosis kit to detect either influenza A or B virus infections", 《J VET MED SCI》, vol. 68, no. 1, pages 35 - 40, XP055221418 *
张培瑞等: "乙型流感病毒单克隆抗体的制备与评价", 《免疫学杂志》, vol. 28, no. 12 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117143242A (en) * 2023-10-30 2023-12-01 南京佰抗生物科技有限公司 Monoclonal antibody composition for resisting Galectin-3 protein and application thereof
CN117143242B (en) * 2023-10-30 2024-03-29 南京佰抗生物科技有限公司 Monoclonal antibody composition for resisting Galectin-3 protein and application thereof

Also Published As

Publication number Publication date
CN116715760B (en) 2023-10-03

Similar Documents

Publication Publication Date Title
CN116715760B (en) Monoclonal antibody composition for resisting influenza B virus nucleocapsid protein and application thereof
CN111220803B (en) Novel coronavirus antibody detection reagent, preparation method thereof and novel coronavirus antibody detection card
CN116693675B (en) Monoclonal antibody composition of anti-influenza A virus nucleocapsid protein and application thereof
CN102735851B (en) Mycoplasma hyopneumoniae multi-recombination antigen ELISA (enzyme-linked immunosorbent assay) detection kit
CN105745542B (en) The assay method of influenza A virus
CN107573417A (en) Mycoplasma pneumoniae chimeric antigen, the antigen detecting agent and both preparation methods
CN107365364A (en) A kind of quick detection kit of Adenovirus Antigen preparation method and the detection adenovirus antibody prepared using the antigen
CN101130765A (en) Reagent kit for detecting syncytial virus of respiratory passage
CN110540595B (en) Preparation method of klebsiella pneumoniae antibody latex microsphere immunochromatography detection test paper
CN110540969B (en) Monoclonal antibody of surface protein of mycoplasma hyopneumoniae and antigen capture ELISA kit
CN101100673A (en) Mycobacterium tuberculosis recombination fusion protein and application thereof
CN110540594B (en) Preparation method of latex microsphere immunochromatographic test paper based on Moraxella catarrhalis surface protein
CN112521462A (en) Equine infectious anemia virus p26-gp90 recombinant protein, and preparation method and application thereof
CN101914563A (en) Mycobacterium tuberculosis 38Kd-16Kd-CFP10 recombinant fusion protein and application thereof
CN102368070A (en) Kit for detecting content of MR-1S (Myofibrillogenesis Regulator-1S) in human plasma and preparation method thereof
CN101692089A (en) Immunochromatographic test paper for detecting mycobacterium bovis antibodies and preparation method thereof
CN101509002B (en) Recombinant rubella virus protein and uses thereof
CN110713523B (en) Detection strip for qualitatively detecting acinetobacter baumannii specific antibody in human serum
CN109456409B (en) Specific antibody group for detecting klebsiella pneumoniae and application thereof
CN113698474A (en) African swine fever polyclonal antibody and African swine fever antigen detection test strip
CN117003869B (en) anti-IL-10 protein monoclonal antibody composition and application
CN105968197B (en) A kind of anti-3 type Ureaplasma urealyticum MB protein antibodies and the immune chromatography reagent kit using the antibody
CN114624447B (en) Test paper for detecting novel coronavirus and preparation process thereof
CN114316039B (en) Kit for rapidly detecting viruses and preparation method thereof
CN102492699B (en) Recombination human herpes simplex virus II protein and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant